These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 31502843)
1. Structural Characterization of Agonist Binding to an A Stamatis D; Lagarias P; Barkan K; Vrontaki E; Ladds G; Kolocouris A J Med Chem; 2019 Oct; 62(19):8831-8846. PubMed ID: 31502843 [TBL] [Abstract][Full Text] [Related]
2. Insights to the Binding of a Selective Adenosine A Lagarias P; Barkan K; Tzortzini E; Stampelou M; Vrontaki E; Ladds G; Kolocouris A J Chem Inf Model; 2019 Dec; 59(12):5183-5197. PubMed ID: 31725294 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterisation of novel adenosine A Barkan K; Lagarias P; Stampelou M; Stamatis D; Hoare S; Safitri D; Klotz KN; Vrontaki E; Kolocouris A; Ladds G Sci Rep; 2020 Nov; 10(1):20781. PubMed ID: 33247159 [TBL] [Abstract][Full Text] [Related]
4. Effects of synthetic A3 adenosine receptor agonists on cell proliferation and viability are receptor independent at micromolar concentrations. Mlejnek P; Dolezel P; Frydrych I J Physiol Biochem; 2013 Sep; 69(3):405-17. PubMed ID: 23184730 [TBL] [Abstract][Full Text] [Related]
5. Structure-Activity Analysis of Biased Agonism at the Human Adenosine A3 Receptor. Baltos JA; Paoletta S; Nguyen AT; Gregory KJ; Tosh DK; Christopoulos A; Jacobson KA; May LT Mol Pharmacol; 2016 Jul; 90(1):12-22. PubMed ID: 27136943 [TBL] [Abstract][Full Text] [Related]
6. Adenosine A3 receptor activation is neuroprotective against retinal neurodegeneration. Galvao J; Elvas F; Martins T; Cordeiro MF; Ambrósio AF; Santiago AR Exp Eye Res; 2015 Nov; 140():65-74. PubMed ID: 26297614 [TBL] [Abstract][Full Text] [Related]
7. Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: insight into the receptor activation switch. Dal Ben D; Buccioni M; Lambertucci C; Kachler S; Falgner N; Marucci G; Thomas A; Cristalli G; Volpini R; Klotz KN Biochem Pharmacol; 2014 Jan; 87(2):321-31. PubMed ID: 24161786 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of N⁶-substituted apioadenosines as potential adenosine A₃ receptor modulators. Toti KS; Moss SM; Paoletta S; Gao ZG; Jacobson KA; Van Calenbergh S Bioorg Med Chem; 2014 Aug; 22(15):4257-68. PubMed ID: 24931275 [TBL] [Abstract][Full Text] [Related]
9. Activation of Adenosine A Ferreira-Silva J; Aires ID; Boia R; Ambrósio AF; Santiago AR Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33007835 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5'-N-ethyluronamide as A1 and A3 adenosine receptor agonists. Baraldi PG; Cacciari B; Pineda de Las Infantas MJ; Romagnoli R; Spalluto G; Volpini R; Costanzi S; Vittori S; Cristalli G; Melman N; Park KS; Ji XD; Jacobson KA J Med Chem; 1998 Aug; 41(17):3174-85. PubMed ID: 9703463 [TBL] [Abstract][Full Text] [Related]
11. Functional expression of adenosine A2A and A3 receptors in the mouse dendritic cell line XS-106. Dickenson JM; Reeder S; Rees B; Alexander S; Kendall D Eur J Pharmacol; 2003 Aug; 474(1):43-51. PubMed ID: 12909194 [TBL] [Abstract][Full Text] [Related]
16. The synthesis of a series of adenosine A3 receptor agonists. Broadley KJ; Burnell E; Davies RH; Lee AT; Snee S; Thomas EJ Org Biomol Chem; 2016 Apr; 14(15):3765-81. PubMed ID: 27001924 [TBL] [Abstract][Full Text] [Related]
17. Docking studies of agonists and antagonists suggest an activation pathway of the A3 adenosine receptor. Kim SK; Gao ZG; Jeong LS; Jacobson KA J Mol Graph Model; 2006 Dec; 25(4):562-77. PubMed ID: 16793299 [TBL] [Abstract][Full Text] [Related]
18. Activation of adenosine A3 receptor reduces early brain injury by alleviating neuroinflammation after subarachnoid hemorrhage in elderly rats. Li P; Li X; Deng P; Wang D; Bai X; Li Y; Luo C; Belguise K; Wang X; Wei X; Xia Z; Yi B Aging (Albany NY); 2020 Nov; 13(1):694-713. PubMed ID: 33253120 [TBL] [Abstract][Full Text] [Related]
19. Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000. Gao ZG; Ye K; Göblyös A; Ijzerman AP; Jacobson KA BMC Pharmacol; 2008 Dec; 8():20. PubMed ID: 19077268 [TBL] [Abstract][Full Text] [Related]
20. A3 Adenosine receptors mediate oligodendrocyte death and ischemic damage to optic nerve. González-Fernández E; Sánchez-Gómez MV; Pérez-Samartín A; Arellano RO; Matute C Glia; 2014 Feb; 62(2):199-216. PubMed ID: 24311446 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]